Nuclera and Cytiva Join Forces to Accelerate Drug Discovery
Nuclera is driven by a single goal: to revolutionize protein expression and optimization. The company is excited to share news of its latest collaboration with Cytiva. Together, the companies are streamlining the production, purification, and characterization of proteins essential for drug research and development—bringing new efficiencies to a process that has traditionally taken months.
This collaboration integrates Nuclera's benchtop eProtein Discovery™ System with Cytiva’s Biacore™ surface plasmon resonance (SPR) technology. The result? The ability to go from protein expression to characterization in just five days.
Proteins account for 95% of drug targets, making rapid access to high-quality protein samples critical to developing treatments that combat disease. At industry-leading conferences like Discovery on Target and PEGS Europe, Nuclera demonstrated this powerful combination in action. Using the eProtein Discovery System, Nuclera successfully produced Bruton’s Tyrosine Kinase (BTK) and Vascular Endothelial Growth Factor (VEGF)—two clinically relevant proteins. These were then functionally characterized using Cytiva’s Biacore SPR system, validating both speed and scientific rigor.
As Dr. Yvonne Tan, our Associate Director of Product, put it: “Collaborating with life science leader Cytiva supports Nuclera in our mission of improving human health. Through this collaboration, we have demonstrated eProtein Discovery’s ability to produce clinically significant proteins that can be used in characterization experiments. Combining eProtein Discovery’s capability to streamline protein production workflows with Cytiva’s Biacore protein characterization systems open a whole new avenue for accelerating drug development.”
Anna Moberg, Senior Manager and Project Manager at Cytiva, also shared her excitement: “The ability of Nuclera’s eProtein Discovery to accelerate protein production and purification complements Cytiva’s Biacore SPR technology by streamlining the upstream protein production process. We look forward to continuing our collaboration to further enhance the production of characterizable proteins for drug development.”
This partnership is believed to mark a major step forward for the drug development community—and for the future of personalized, efficient therapeutics.
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Protein analytics
Protein analytics provides a deep insight into these complex macromolecules, their structure, function and interactions. It is essential for discovering and developing biopharmaceuticals, understanding disease mechanisms, and identifying therapeutic targets. Techniques such as mass spectrometry, Western blot and immunoassays allow researchers to characterize proteins at the molecular level, determine their concentration and identify possible modifications.
Topic world Protein analytics
Protein analytics provides a deep insight into these complex macromolecules, their structure, function and interactions. It is essential for discovering and developing biopharmaceuticals, understanding disease mechanisms, and identifying therapeutic targets. Techniques such as mass spectrometry, Western blot and immunoassays allow researchers to characterize proteins at the molecular level, determine their concentration and identify possible modifications.